Ovid Therapeutics (OVID) Change in Account Payables (2016 - 2026)

Ovid Therapeutics (OVID) has reported Change in Account Payables for 11 consecutive years, with -$1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Account Payables fell 175.32% year-over-year to -$1.5 million; the trailing twelve-month figure through Jun 2026 stood at $122000.0 (up 115.86% YoY), and the FY2025 full-year result was -$1.2 million, down 141.02% from the prior year.
• Change in Account Payables fell to -$1.5 million in Q2 2026 per OVID's latest filing, from $3.6 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $3.6 million in Q1 2026 and bottomed at -$4.9 million in Q1 2022.
• Historically, Change in Account Payables has averaged -$169674.2 across 5 years, with a median of $69500.0 in 2024.
• The sharpest annual moves came in 2025 and 2026: Change in Account Payables slumped 1060.75% in 2025, then soared 391.79% in 2026.
• Over 5 years, Change in Account Payables stood at $919844.0 in 2022, then surged by 170.26% to $2.5 million in 2023, then plunged by 80.65% to $481000.0 in 2024, then tumbled by 48.86% to $246000.0 in 2025, then slumped by 713.01% to -$1.5 million in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$1.5 million, $3.6 million, and $246000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.